Deficiencies in immune function that accumulate during cancer immunoediting lead to a progressive escape from host immune surveillance. Therapies that correct or overcome these defects could have a powerful impact on cancer management, but current knowledge of the types and mechanisms of immune escape are still incomplete. Here we report a novel mechanism of escape from T cell immunity that is caused by reduction in levels of the Delta family Notch ligands DLL1 and DLL4 in hematopoietic microenvironments. An important mediator of this effect was an elevation in the levels of circulating vascular endothelial growth factor (VEGF).
Introduction
Immunotherapy is theoretically able to specifically eliminate malignant cells with low toxicity.
Unfortunately while hints of activity have been observed, clinical immunotherapy efforts have proven largely ineffective to date (1, 2) . We now recognize that at least part of this failure is due to the numerous immune-regulatory circuits influenced by cancers, which alter the differentiation and function of bone marrow-derived immune cells, including T cells. Both the Notch and VEGF signaling pathways are well known to regulate the function and differentiation of immune cells, but the interplay of these two and the therapeutic implications of this finding in cancer are poorly understood.
In mice, Notch signaling consists four receptors (Notch1-Notch4), two Serrate-like ligands (Jagged1, Jagged2), and three Delta-like ligands (DLL1, DLL3 and DLL4) (3, 4) . DLL4 and VEGF are both genes where loss of a single allele results in embryonic lethality due to failure to form a functional vasculature (5, 6) . This fact provides genetic evidence for the importance of both VEGF and Notch signaling in vascular development. Many other studies have demonstrated the interplay of Notch and VEGF in angiogenesis (7) . VEGF induces DLL4 ligand expression in tumor blood vessels (8, 9) , and subsequent DLL4-mediated Notch signaling regulates the differentiation and proliferation of endothelial cells responsive to VEGF and thereby promotes the timely formation of a functional and well-organized vascular network (7) .
In addition, Notch and VEGF signaling also play essential roles in immune cell development and differentiation. Inactivation of Notch1 signaling results in impairment of T lymphopoiesis accompanied by promotion of B cell development (10, 11) . Conversely, retroviral transduction of bone marrow precursors with the Notch1 intracellular domain results in extrathymic T cell development and a simultaneous block of bone marrow B cell development (12, 13) . Delta-like family ligands also play critical roles in T lymphopoiesis. Overexpression of Delta1 or Delta4 in bone marrow precursors in vivo, or expression of DLL1 or DLL4 in stromal cells in vitro, leads to induction of T cell development and suppression of B cell development (14) (15) (16) (17) (18) (19) . A recent study further shows that DLL4 is the essential and non-redundant Notch1 ligand responsible for T cell lineage commitment (20) . One important feature of Delta-like family ligands is that they act in a dose/density dependent manner (5, 18, 21) . Higher density of Delta1 promotes T cell development and inhibits B cell development, while relatively lower density of Delta1 promotes both T and B cell development (22) . The gain and loss of function studies clearly demonstrate that Notch signaling is necessary and sufficient for T-versus B-lineage commitment and that both DLL1 and DLL4 are able to modulate T cell development (3, 4) .
VEGF and its receptors are also widely expressed in the hematopoietic system and regulate hematopoiesis (6) . In tumor bearing hosts, elevated levels of VEGF affect the differentiation and maturation of immune cells, including T cells, and thus contribute to cancer-associated immunodeficiency (23) (24) (25) (26) . However, little is known about the interplay between Notch and VEGF signaling pathways in the immune system, and specifically in cancer-associated immunosuppression.
Here we show that tumor growth down-regulates expression of DLL1 and DLL4 in the hematopoietic environment and elevated circulating VEGF is one causative factor. Selective stimulation of DLL1-Notch signaling rescues the observed tumor-associated T-cell alterations and dramatically slows tumor growth. Thus this study suggests the novel concept that stimulation of DLL1-Notch signaling may be an effective strategy to overcome tumor-associated T cell immunosuppression.
Materials and Methods

Cell lines
Lewis Lung Carcinoma (LLC) cell lines were obtained from the American Type Culture Collection (Manassas, VA) less than 6 months ago. D459 cells are murine fibroblasts malignantly transformed in our lab by transfection of ras and p53 (34) . Thus our lab is the primary source of these cells and we regularly go back to reference stocks to ensure fidelity. No other identity testing was done, only routine sterility and mycoplasma testing. 
Reagents
DC101, a rat neutralizing monoclonal antibody specifically against mouse VEGFR-2, was a generous gift from ImClone system. The matched control antibody Rat IgG was purchased from Sigma-Aldrich. VEGF -165 and its mutants (KDR-sel and Flt-sel) were generous gifts from Genentech Inc (27) . Osmotic pumps were purchased from Alzet.
VEGF Administration
VEGF -165 , KDR-sel (VEGFR2-sel) or Flt-sel (VEGFR1-sel) was delivered into mice via Alzet osmotic pumps as previously described (26) for 28 days at 50 ng/h. Control pumps were filled with phosphate-buffered saline (PBS). Those mice were treated by intraperitoneal injection of rat IgG or DC101 starting 1 day after pump implantation and every 3 days thereafter with dose of 40 mg/Kg (28).
Quantitative RT-PCR in cancer patient samples
We collected de-identified excess archived paraffin-embedded BM samples resected for clinical indications from lung cancer patients without bone morrow metastases before any treatment (4 squamous cell carcinoma, 3 adenocarcinoma, 1 transitional cell carcinoma, and 1 large cell carcinoma). We used de-identified archived excess bone marrow samples from femurs of age-matched individuals undergoing clinically indicated hip replacement as controls. We extracted RNA from formalin-fixed paraffin-embedded bone marrow samples by FFPE RNA isolation kit (Ambion) and used a set of specific primers described earlier (29) to analyze the transcription of Delta1 and Hes1 in BM.
Quantitative RT-PCR in mouse samples
Total RNA was obtained using TRIzol (GIBCO-BRL, Invitrogen Corp. 
Bone marrow transduction and transplantation
Retroviral constructs MigR1-DLL1 and Mig-R1 were generous gifts from Sunnybrook and Women's College Health Science Centre, Canada (17) . Retroviral supernatants were generated using the Bosc23 packaging cell line. BM cells were infected with retrovirus as previously described (12, 14) . 
Western Blotting
Proteins were extracted from splenocytes, separated by 10% SDS-PAGE and transferred to nitrocellulose membranes (Amersham Biosciences). Antibodies to Delta-like 1 or Delta-like 4 (sc-9102 or sc-18641, Santa Cruz Biotechnology) were used. Protein content was normalized using mouse monoclonal anti-β-actin (Sigma) or anti-mouse GAPDH (sc-25778, Santa Cruz Biotechnology). 
Flow cytometric (FCM) analysis
Results
Tumor-derived factors attenuate DLL1 and DLL4 levels in the BM of cancer patients and tumor-bearing animals
Notch signaling is highly dose-and context-dependent and plays diverse roles in cancer (30) . DLL1 and DLL4 are two critical Notch ligands involved in T cell development and tumor angiogenesis (4, 7). We studied the transcriptional levels of Delta1 (a Notch ligand) and Hes1 (a Notch target gene) in the bone marrow (BM) of cancer patients and found them to be present at reduced levels compared to those from tumor-free donors (Fig. 1A) , suggesting that tumors can attenuate Notch signaling in the BM microenvironment. Consistent with this observation, the transcriptional levels of DLL1 and DLL4 were also significantly decreased in bone marrow cells from tumor-bearing mice (Fig. 1B) . Expression of DLL1 and DLL4 protein was also dramatically decreased in splenocytes from tumor-bearing mice ( Supplementary Fig. 1 ). We then sought to determine the functional consequences of these alterations.
Over-expressing DLL1 alone in BM precursors significantly improves T cell immune responses and inhibits tumor growth
To examine the effect of alterations in DLL1 expression in the hematopoietic environment on tumor growth, we transduced BM precursors with a DLL1-carrying-retrovirus (Mig-DLL1), or a control retrovirus (MigR1) both of which also express a GFP marker ( Supplementary Fig. 2 ). The transduced BM precursors were then transplanted into lethally irradiated recipient mice, which are referred to here as DLL1-mice and MigR1-mice. Thirteen weeks post-transplantation, we routinely observed 60 to 70% GFP positive cells in peripheral blood cells, confirming successful transduction and reconstitution (data not shown). We then inoculated MigR1-mice or DLL1-mice with D459 tumor cells 8-weeks after BM transplantation. We observed a remarkable inhibition of tumor growth in DLL1-mice compared with MigR1-mice ( Fig. 2A) . This inhibition was evident as early as Day 21 and the tumor size remained nearly unchanged through Day 35 ( Fig. 2A) . These data show that over-expressing DLL1 alone significantly inhibits tumor growth.
Notch signaling is known to play a critical role in T-versus B-cell fate decisions, and both DLL1 and DLL4 are able to promote T cell development (3, 4) . We have previously shown that tumorderived factors inhibit T lymphocyte development and function (25, 26 that reduced tumor growth in DLL1-mice could be mediated by enhanced T cell activity. We observed a significant decrease of the fraction of T cells as well as the T(CD3e)/B(CD19) ratios in the spleens of MigR1-mice inoculated with D459 tumors (Fig. 2B) . Conversely, overexpression of DLL1 alone in BM precursors rescued these T cell alterations as tumor-bearing DLL1 animals showed no significant decrease in the proportion of splenic T cells and actually a significant increase in splenic T(CD3e)/B(CD19) ratios (Fig. 2B) .
Production of IFN-γ is a critical indicator of Th1-type cytotoxic T-cell function that is important for anti-tumor immune responses. Upon anti-CD3 stimulation, we found that the number of IFN-γ producing T cells (per 10 5 T cells) was dramatically increased in DLL1-mice bearing D459
tumors, compared with MigR1-mice bearing D459 tumors (Fig. 2C) . We also observed more tumor infiltrating T cells in DLL1-mice than in MigR1-mice (data not shown). Importantly, these infiltrating T cells (and the peripheral blood T cell fractions) had the same fractional GFP expression as did bulk circulating nucleated cells, suggesting that this was not a cell-autonomous effect (requiring DLL1 expression in the T-cells themselves), but rather a consequence of increased expression in the hematopoietic environment in which they develop (data not shown).
Together, our data suggest that over-expressing DLL1 alone significantly enhances T cell immune responses and inhibits tumor growth.
Elevated circulating VEGF inhibits T cell development by downregulating the levels of DLL1 and DLL4 in the hematopoietic environment
Higher levels of serum VEGF have been reported in patients with many types of cancers, such as no-small-cell lung cancer (31) . In animal models, circulating VEGF has been found to be derived from not only tumor cells, but also stromal cells, such as immune cells and endothelial cells (32, 33) . We have previously shown that elevated circulating VEGF alters host hematopoiesis including the inhibition of T lymphopoiesis (26) . We therefore hypothesized that VEGF is one of the mediators to inhibit expression of DLL1 and DLL4 in tumor-bearing hosts. As we observed in tumor-bearing mice, we found that transcriptional levels of DLL1 and DLL4 in BM cells of non-tumor-bearing mice were significantly decreased in mice infused with recombinant VEGF at levels observed in tumor-bearing mice (Fig. 3A) . Simultaneous administration of a VEGFR-2 specific antibody (DC101) reversed this effect (Fig. 3A) . Expression of DLL1 and DLL4 protein 
in splenocytes was also dramatically decreased in VEGF-infused mice as was seen in tumorbearing animals, and again DC101 treatment reversed this effect (Fig 3B) . Similarly, a VEGFR-2 but not a VEGFR-1 specific ligand dramatically decreased expression of DLL1 and DLL4 protein in the spleen (Fig. 3B) . Together, these data indicate that VEGFR-2 signaling decreases the levels of DLL1 and DLL4 in the hematopoietic environment, consistent to the effects observed in tumor-bearing mice.
In experiments designed to determine whether lower levels of DLL1 and DLL4 in the BM microenvironment altered Notch signaling, we found that transcriptional levels of Hes1 and Deltex1 (Notch target genes) were significantly decreased in VEGF-infused mice compared to those of PBS-infused mice (Fig. 3C) , and DC101 treatment totally reversed this effect. We then implanted osmotic pumps containing recombinant VEGF or PBS diluent into MigR1-mice and DLL1-mice. The T cell data from spleen and thymus indicate that overexpressing DLL1 alone overcomes the inhibition of VEGF on T cell development (Fig. 4) . Collectively, our data show that elevated circulating VEGF inhibits T cell development by downregulating the levels of DLL1 and DLL4 in the hematopoietic environment.
T cells contribute to the tumor growth inhibition induced by selectively activated DLL1-
Notch signaling
We also developed a novel reagent we refer to as clustered DLL1, which is a complex of DLL1- (Fig 5A and Supplementary Fig.   3A ). To determine its effect on tumor growth in vivo, we treated D459 tumor-bearing mice with soluble clustered DLL1 or anti-Fc antibody-avidin complex as control. Like the DLL1 overexpression data shown in Figure 2A (C57BL/6), demonstrating that this effect is not model-specific (Fig. 5C) . Together, our data show that soluble clustered DLL1 treatment dramatically inhibits tumor growth.
We then analyzed the effects of soluble clustered DLL1 treatment on T cell function. As observed for the DLL1 vector transduction in Figures 2B and 2C , soluble clustered DLL1 treatment increases the transcriptional levels of Hes1 and Deltex1 (Notch target genes) in the BM (Fig. 6A) , prevents the decrease in the T cell fraction in tumor-bearing animals ( Supplementary   Fig. 3B ) and significantly improves T cell IFN-γ production (Fig. 6B ). This suggests that DLL1 treatment improves T cell immune responses.
To test the contribution of T cells in tumor growth inhibition ( Fig. 2A and 5 ), we performed two kinds of experiments in two different tumor models (Fig. 5) . First, we implanted LLC in both immune competent C57BL/6 mice and immune deficient RAG1 (Fig 5B) . Together, our data suggest that CD8 T cells contribute to tumor growth inhibition induced by soluble clustered DLL1 treatment.
Discussion
Compelling evidence suggests that immune cells play an important role in the control of malignant tumor growth (35, 36) . However, tumors circumvent this control by interfering with the induction and function of these immune responses, both systemically and in the tumor microenvironment. Thus, a major challenge for cancer immunotherapy is to use advances in cellular and molecular immunology to develop strategies that effectively and safely augment antitumor immune responses (37) .
In this study, we describe a novel observation that tumors can systemically suppress host T cell On the contrary, there are abundant data supporting a specific role for the Delta family ligands in T lymphopoiesis. Stromal cell overexpression of DLL1 or DLL4 is sufficient to induce T cell development and inhibit B cell development in vitro, but stromal cells expressing Jagged1 do not (16, 17, 39) . Consistent with these observations, our data showed that over-expressing DLL1 alone in BM precursors promotes T cell development while suppressing B cell development (Fig.   4 ). The effects may be different depending on signal intensity as well, as relatively lower vivo by chronic treatment with a γ-secretase inhibitor also caused thymic atrophy, decreased total thymocytes as well as T cell subtypes in thymus (45) .
All of these results indicate that stronger Notch signaling by Delta family ligands induces T cell development and inhibits B cell development, whereas reduction in Notch signaling inhibits T cell development and favors B cell differentiation. This is consistent with a causative relationship that we find in this study between the inhibition of T cell development and decreased Notch signaling in tumor-bearing animals and VEGF-infused mice.
In contrast to the induction of DLL4 in tumor vasculature (9), we observed a striking reduction of DLL1 and DLL4 in the hematopoietic environment ( Fig. 1 and Supplementary Fig. 1 ). The difference is certainly due to the different cell types and tissues studied -local effects on vascular endothelial cells vs. systemic effects on the hematopoietic environments we studied here. Dynamic, temporally and spatially regulated expression of the mouse DLL1 gene in distinct tissues and cell types is frequently observed in embryonic development (46) . While DLL4 shows substantial homology with DLL1, others also have shown that they have distinct functions and cannot completely substitute for each other (47) . Heterozygous DLL4, but not DLL1, knockouts have a vascular embryonic lethal phenotype (5). Either DLL1 or DLL4 alone is sufficient to support T cell development, but over-expression DLL4, not DLL1, results in T cell leukemia (14) (15) (16) (17) . Consistent with these reports, we didn't observe ectopic T cell development and T cell leukemia in these DLL1 over-expressing mouse models during our experimental period. DLL4 thus potently affects both vascular development and T cell development, but DLL1 appears more selectively important for T cell maturation. Currently we haven't dissected which Notch receptor mediates the effect of DLL1 in our models. Notch1 may mediate the restoration of T cell development (12, 13) and Notch2 seems to mediate the improvement of T cell function (48) .
Tumors suppress expression of both DLL1 and DLL4 in the bone marrow and spleen and induce DLL4 in tumor-adjacent endothelial cells (7) reflecting the distinct and regional immunologic and vascular effects of Notch signaling. Our data suggest that selectively promoting DLL1-mediated signaling reverses T cell-mediated immunosuppression while avoiding the promotion of tumor angiogenesis proposed for DLL4. 
